
1. eur rev med pharmacol sci. 2018 oct;22(20):7024-7033. doi:
10.26355/eurrev_201810_16174.

optimising management patients hepatitis c virus age of
direct-acting antivirals: results delphi consensus.

di marco v(1), alberti a, angarano g, colombo m, di perri g, gaeta gb, ippolito
g, mangia a, pasqualetti p, craxì a.

author information: 
(1)sezione di gastroenterologia e epatologia, dipartimento biomedico di medicina 
interna e specialistica, università di palermo, palermo, italy.
vito.dimarco@unipa.it.

objective: optimize management patients chronic hepatitis c virus 
(hcv).
materials methods: developed two questionnaires determine italian
healthcare professionals' opinions overall management hcv chronic liver
disease use direct-acting antivirals (daas) treatment hcv. a
delphi consensus method using rand/ucla appropriateness method used to
determine opinions expert panel (ep) specialists.
results: overall 443 physicians 167 italian centres completed two
questionnaires. ep confirmed importance collaboration general
practitioners (gps) hcv testing high-risk groups, agree on
treating patients 80 years age daas. 90% agreed was
important quantify hcv-rna, determine genotype, test anti-hiv and
hbsag starting daas. transient elastography (fibroscan®) used >90% 
to evaluate stage liver fibrosis serum biomarkers used <20%.
adherence therapy, drug-drug interactions possibility treating
advanced liver disease decisive factors therapy choice. monthly
monitoring therapy considered appropriate 80% favor of
hcv-rna testing 24 weeks end therapy confirm sustained
virological response (svr). 80% agreed necessary continue
follow-up patients advanced fibrosis/cirrhosis.
conclusions: scientific organizations review guideline
recommendations facilitate access daas.

doi: 10.26355/eurrev_201810_16174 
pmid: 30402870  [indexed medline]

